

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from electronic originals
(may include minor formatting differences from printed original)



130th MAINE LEGISLATURE

FIRST SPECIAL SESSION-2021

Legislative Document

No. 1729

S.P. 574

In Senate, May 27, 2021

Resolve, To Assess the Feasibility of the Production of Insulin in Maine

(AFTER DEADLINE)

Approved for introduction by a majority of the Legislative Council pursuant to Joint Rule 205.

Received by the Secretary of the Senate on May 25, 2021. Referred to the Committee on Health and Human Services pursuant to Joint Rule 308.2 and ordered printed.

A handwritten signature in black ink, appearing to read "D M Grant".

DAREK M. GRANT
Secretary of the Senate

Presented by Senator STEWART of Aroostook.
Cosponsored by Representative JAVNER of Chester and
Senator: MOORE of Washington, Representatives: CONNOR of Lewiston, GRIFFIN of
Levant.

1 **Sec. 1. Commission established. Resolved:** That the Department of Health and
2 Human Services shall convene a commission consisting of the following 11 members:

- 3 1. The Commissioner of Health and Human Services or the commissioner's designee;
- 4 2. A representative of the Department of Health and Human Services, Maine Center
5 for Disease Control and Prevention;
- 6 3. A representative of the Maine Biomedical Research Board as established in the
7 Maine Revised Statutes, Title 5, section 13104;
- 8 4. A representative of the Department of Professional and Financial Regulation, Maine
9 Board of Pharmacy;
- 10 5. A representative of the Department of Professional and Financial Regulation,
11 Bureau of Insurance;
- 12 6. A representative of the University of Maine System;
- 13 7. A resident of the State receiving treatment for diabetes or a representative of an
14 organization that represents or advocates for residents of the State receiving treatment for
15 diabetes;
- 16 8. Two physicians licensed to practice within the State having expertise in the
17 treatment of diabetes and related complications;
- 18 9. A research scientist having expertise in the synthesis or production of drugs or
19 biologics, including insulin; and
- 20 10. A representative of hospitals and health care providers within the State.

21 **Sec. 2. Feasibility assessment. Resolved:** That the commission established in
22 section 1 shall assess the feasibility of producing insulin in the State through the University
23 of Maine System and other appropriate institutions or through a public-private partnership
24 between the University of Maine System, other appropriate institutions and a licensed drug
25 manufacturer. The commission shall also assess the feasibility of providing the insulin
26 produced to low-income residents of the State at low or no cost through hospitals,
27 pharmacies and health care providers in the State or at a reduced cost on a means-tested
28 basis. In its assessment, the commission shall consider various factors including:

- 29 1. The number of low-income residents of the State who currently require insulin;
- 30 2. The ability of the University of Maine System by itself, in partnership with another
31 appropriate institution or through a public-private partnership with a licensed drug
32 manufacturer to produce insulin in an amount sufficient to fulfill the needs of low-income
33 residents of the State who require insulin;
- 34 3. Any long-term cost savings and revenue generation for the State and the University
35 of Maine System;
- 36 4. Any long-term cost savings and other benefits to low-income residents of the State
37 who would receive insulin at low or no cost;
- 38 5. Any costs to the University of Maine System and to the State to produce and
39 distribute insulin, including additional administrative costs;

